monashee investment management is an investment institution focusing on healthcare industry. It has participated in the investment of many innovative medical companies, showing its vision and strengths in this field. For example, it invested in the merger of regenerative tissue and organ development company humacyte and SPAC company Alpha Healthcare Acquisition Corp. It also participated in the PIPE financing after the merger of prescription digital therapeutics company Better Therapeutics and Mountain Crest Acquisition Corp II. In addition, monashee also invested in the surgical robot company Memic’s merger with MedTechAcquisition Corporation. Through these cases, we can see that monashee investment management has rich experience and resources in innovative medical investment, and is optimistic about the growth potential of these cutting-edge healthcare companies.
monashee participates in humacyte’s SPAC merger and expects its annual sales to exceed $10 billion
In August 2021, regenerative tissue and organ development company Humacyte announced the completion of a merger with SPAC company Alpha Healthcare Acquisition Corp. Humacyte obtained $175 million PIPE financing and $70 million cash proceeds from the merger, totaling $245 million. The PIPE investors included healthcare-focused funds such as Fresenius Medical Care, OrbiMed, and monashee investment management. After the merger, Humacyte was expected to be listed on Nasdaq with the stock code “HUMA”. Humacyte has a pipeline of regenerative medicine products including human acellular vessels (HAV). It is estimated that if HAV finally gets FDA approval and enters the market, Humacyte’s pipeline products may reach $12.1 billion in annual sales.
monashee participates in better therapeutics’ SPAC merger and PIPE financing
In October 2021, Better Therapeutics, a prescription digital therapeutics company focusing on cognitive behavioral therapy for cardiometabolic diseases, completed a merger with Mountain Crest Acquisition Corp II and started trading on Nasdaq under the stock code “BTTX”. This $70 million financing round included PIPE financing from investors such as Farallon Capital Management, RS Investments, Sectoral Asset Management and monashee investment management. The funds will be used to advance clinical trials and FDA submissions, as well as developing Better Therapeutics’ pipeline. This case represents an important milestone for the new digital therapeutics sector. It shows monashee’s vision in innovative medical investment fields.
monashee invests in the surgical robot company memic’s SPAC merger
In August 2021, Israeli surgical robot company Memic announced that it has signed a merger agreement with MedTechAcquisition Corporation. After the merger, the combined company is expected to have a stock value of over $1 billion. Memic has developed a unique surgical robot technology and its product Hominis is the first and only FDA-approved surgical robot with human-level flexibility and mobility. Compared to existing technologies, Hominis takes up minimum space in operating rooms and has significant cost advantages. After the merger, monashee will be one of the board members of the combined company, together with other healthcare funds and investors. This again shows monashee’s capabilities in identifying and investing in cutting-edge medtech innovations.
Through these cases of Humacyte, Better Therapeutics and Memic, we can see that monashee investment management has rich experience in healthcare investment, especially in identifying and supporting innovative companies with growth potentials. Its investment portfolio covers various hot fields such as digital therapeutics, surgical robots, regenerative medicine etc. Monashee’s participation and resources will also help accelerate these companies’ development and commercialization.